OCCULT PROSTATE-CANCER IN MEN WITH LOW SERUM TESTOSTERONE LEVELS

Citation
A. Morgentaler et al., OCCULT PROSTATE-CANCER IN MEN WITH LOW SERUM TESTOSTERONE LEVELS, JAMA, the journal of the American Medical Association, 276(23), 1996, pp. 1904-1906
Citations number
24
Categorie Soggetti
Medicine, General & Internal
ISSN journal
00987484
Volume
276
Issue
23
Year of publication
1996
Pages
1904 - 1906
Database
ISI
SICI code
0098-7484(1996)276:23<1904:OPIMWL>2.0.ZU;2-J
Abstract
Objective.-To determine the prevalence of occult prostate cancer in me n with low serum total testosterone or free testosterone levels. Desig n.-Retrospective analysis of a consecutive series of men. Setting.-Aca demic teaching hospital. Patients.-Seventy-seven men with low total te stosterone or free testosterone levels, with normal results of digital rectal examination and prostate-specific antigen (PSA) levels of 4.0 ng/mL or less. The mean age was 58 years. Interventions.-Sextant prost ate needle biopsies with ultrasound guidance. Main Outcome Measures.-R esults of prostate needle biopsies, transrectal ultrasound, prostate v olume, PSA level, PSA density, total and free testosterone levels. Res ults.-Prostate cancer was identified in 14% (11/77) of the entire grou p and in 10 men (29%) aged 60 years or older. The median age for men w ith cancer was 64 years. Histologic examination showed Gleason scores of 6 or 7 for all cancers. No significant differences were noted betwe en the cancer and benign groups with regard to PSA level, PSA density, prostate volume, total testosterone level, or free testosterone level . Conclusions.-A high prevalence of biopsy-detectable prostate cancer was identified in men with low total or free testosterone levels despi te normal PSA levels and results of digital rectal examination. These data suggest that (1) digital rectal examination and PSA levels are in sensitive indicators of prostate cancer in men with low total or free testosterone levels, and (2) PSA levels may be altered by naturally oc curring reductions in serum androgen levels.